As BRAF/NRAS mutational status is also thought to predict targeted therapy response in melanoma, we further sub-stratified the groups according to CDK2 melanoma cell lines that harbored mutations in either BRAF V600E or NRAS. The RNA levels of CDK2 correlated well with levels of CDK2 protein expression. The gene discussed is NRAS; the disease is melanoma.